H.C. Wainwright Reiterates Buy Rating on Citius Pharmaceuticals (CTXR)

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $4.00 price target on Citius Pharmaceuticals (NASDAQ: CTXR).

The analyst commented: "Citius recognizes revenue when wholesalers order LYMPHIR, not when institutions order from wholesalers. Institutional vial orders from wholesalers rose 31% sequentially, to 926 vials from 708 in 2QFY26. Management indicated that wholesaler orders have begun to reflect the increase in ordering institutions and vial demand. July institutional orders reached 383 vials, the largest monthly total to date and up 25% versus the average monthly order volume in 2QFY26. In our view, while the increased demand is encouraging, quarterly revenue could remain lumpy until wholesaler restocking synchronizes with pull-through. We project 4QFY26 revenues of $2.9M and FY26 revenues of $10.1M. We maintain our Buy rating on CTXR and our 12-month price target of $4.0 per diluted share."

For an analyst ratings summary and ratings history on Citius Pharmaceuticals click here. For more ratings news on Citius Pharmaceuticals click here.

Shares of Citius Pharmaceuticals closed at $0.57 yesterday.

You May Also Be Interested In

• Meta's Muse AI to counter China models with subscribers, not ads, Alexandr Wang says - Nikkei
• Summit Therapeutics and Lunit partner on AI pathology for cancer research
• Honda to sell Mitsubishi Triton-based pickup truck in ASEAN by 2028